Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration

Expert consensus mandates retesting for eradication of Helicobacter pylori infection after treatment, but it is not clear how many patients are actually retested. We evaluated factors associated with retesting for H pylori in a large, nationwide cohort. We performed a retrospective cohort study of p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical gastroenterology and hepatology 2021-02, Vol.19 (2), p.305-313.e1
Hauptverfasser: Kumar, Shria, Metz, David C., Kaplan, David E., Goldberg, David S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 313.e1
container_issue 2
container_start_page 305
container_title Clinical gastroenterology and hepatology
container_volume 19
creator Kumar, Shria
Metz, David C.
Kaplan, David E.
Goldberg, David S.
description Expert consensus mandates retesting for eradication of Helicobacter pylori infection after treatment, but it is not clear how many patients are actually retested. We evaluated factors associated with retesting for H pylori in a large, nationwide cohort. We performed a retrospective cohort study of patients with H pylori infection (detected by urea breath test, stool antigen, or pathology) who were prescribed an eradication regimen from January 1, 1994 through December 31, 2018 within the Veterans Health Administration (VHA). We collected data on demographic features, smoking history, socioeconomic status, facility poverty level and academic status, and provider specialties and professions. The primary outcome was retesting for eradication. Statistical analyses included mixed-effects logistic regression. Of 27,185 patients prescribed an H pylori eradication regimen, 6486 patients (23.9%) were retested. Among 7623 patients for whom we could identify the provider who ordered the test, 2663 patients (34.9%) received the order from a gastroenterological provider. Female sex (odds ratio, 1.22; 95% CI, 1.08–1.38; P = .002) and history of smoking (odds ratio, 1.24; 95% CI, 1.15–1.33; P < .001) were patient factors associated with retesting. There was an interaction between method of initial diagnosis of H pylori infection and provider who ordered the initial test (P < .001). There was significant variation in rates of retesting among VHA facilities (P < .001). In an analysis of data from a VHA cohort of patients with H pylori infection, we found low rates of retesting after eradication treatment. There is significant variation in rates of retesting among VHA facilities. H pylori testing is ordered by nongastroenterology specialists two-thirds of the time. Confirming eradication of H pylori is mandatory and widespread quality assurance protocols are needed.
doi_str_mv 10.1016/j.cgh.2020.03.059
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7541590</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542356520304365</els_id><sourcerecordid>2388815733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-c624e93a82a243ba824f77275c61fd37cd792962983a1892035b34ee4b32bf4f3</originalsourceid><addsrcrecordid>eNp9kU9vEzEQxVcIREvhA3BBPnLJ4r_rtZCQoqrQSpGQqsLV8nrHiaNdO9hOUQ98d5wmVHDhNCPPez-P5jXNW4Jbgkn3Ydva9aalmOIWsxYL9aw5J4LThZSEPz_1THTirHmV8xZjqriSL5szRqmklIvz5tcq_kS3pkBG0aFbqE3xYY1cTOgqmdFbU3wMh-E1TN7GwdgCCe0eppg8ugkO7KNg6Q7PdwlMmSEU5AMqG0DfKzGZkKvbTGWDluPsg88lPWJfNy-cmTK8OdWL5tvnq7vL68Xq65eby-VqYbkgZWE7ykEx01NDORtq5U5KKoXtiBuZtKNUVHVU9cyQXlHMxMA4AB8YHRx37KL5dOTu9sMMo60LJjPpXfKzSQ86Gq__nQS_0et4r6XgRChcAe9PgBR_7OuN9OyzhWkyAeI-a8r6vidCMlal5Ci1KeacwD19Q7A-xKa3usamD7FpzHSNrXre_b3fk-NPTlXw8SiAeqV7D0ln6yFYGH2qAegx-v_gfwO6Dqp2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2388815733</pqid></control><display><type>article</type><title>Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Kumar, Shria ; Metz, David C. ; Kaplan, David E. ; Goldberg, David S.</creator><creatorcontrib>Kumar, Shria ; Metz, David C. ; Kaplan, David E. ; Goldberg, David S.</creatorcontrib><description>Expert consensus mandates retesting for eradication of Helicobacter pylori infection after treatment, but it is not clear how many patients are actually retested. We evaluated factors associated with retesting for H pylori in a large, nationwide cohort. We performed a retrospective cohort study of patients with H pylori infection (detected by urea breath test, stool antigen, or pathology) who were prescribed an eradication regimen from January 1, 1994 through December 31, 2018 within the Veterans Health Administration (VHA). We collected data on demographic features, smoking history, socioeconomic status, facility poverty level and academic status, and provider specialties and professions. The primary outcome was retesting for eradication. Statistical analyses included mixed-effects logistic regression. Of 27,185 patients prescribed an H pylori eradication regimen, 6486 patients (23.9%) were retested. Among 7623 patients for whom we could identify the provider who ordered the test, 2663 patients (34.9%) received the order from a gastroenterological provider. Female sex (odds ratio, 1.22; 95% CI, 1.08–1.38; P = .002) and history of smoking (odds ratio, 1.24; 95% CI, 1.15–1.33; P &lt; .001) were patient factors associated with retesting. There was an interaction between method of initial diagnosis of H pylori infection and provider who ordered the initial test (P &lt; .001). There was significant variation in rates of retesting among VHA facilities (P &lt; .001). In an analysis of data from a VHA cohort of patients with H pylori infection, we found low rates of retesting after eradication treatment. There is significant variation in rates of retesting among VHA facilities. H pylori testing is ordered by nongastroenterology specialists two-thirds of the time. Confirming eradication of H pylori is mandatory and widespread quality assurance protocols are needed.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2020.03.059</identifier><identifier>PMID: 32272245</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Antibiotic ; Breath Tests ; Drug Therapy, Combination ; Female ; Helicobacter Infections - diagnosis ; Helicobacter Infections - drug therapy ; Helicobacter pylori ; Humans ; Proton Pump Inhibitors - therapeutic use ; Resistance ; Response to Therapy ; Retrospective Studies ; Risk Factor ; Treatment Outcome ; Veterans Health</subject><ispartof>Clinical gastroenterology and hepatology, 2021-02, Vol.19 (2), p.305-313.e1</ispartof><rights>2021 AGA Institute</rights><rights>Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-c624e93a82a243ba824f77275c61fd37cd792962983a1892035b34ee4b32bf4f3</citedby><cites>FETCH-LOGICAL-c451t-c624e93a82a243ba824f77275c61fd37cd792962983a1892035b34ee4b32bf4f3</cites><orcidid>0000-0002-3839-336X ; 0000-0001-9745-2676</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2020.03.059$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32272245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar, Shria</creatorcontrib><creatorcontrib>Metz, David C.</creatorcontrib><creatorcontrib>Kaplan, David E.</creatorcontrib><creatorcontrib>Goldberg, David S.</creatorcontrib><title>Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Expert consensus mandates retesting for eradication of Helicobacter pylori infection after treatment, but it is not clear how many patients are actually retested. We evaluated factors associated with retesting for H pylori in a large, nationwide cohort. We performed a retrospective cohort study of patients with H pylori infection (detected by urea breath test, stool antigen, or pathology) who were prescribed an eradication regimen from January 1, 1994 through December 31, 2018 within the Veterans Health Administration (VHA). We collected data on demographic features, smoking history, socioeconomic status, facility poverty level and academic status, and provider specialties and professions. The primary outcome was retesting for eradication. Statistical analyses included mixed-effects logistic regression. Of 27,185 patients prescribed an H pylori eradication regimen, 6486 patients (23.9%) were retested. Among 7623 patients for whom we could identify the provider who ordered the test, 2663 patients (34.9%) received the order from a gastroenterological provider. Female sex (odds ratio, 1.22; 95% CI, 1.08–1.38; P = .002) and history of smoking (odds ratio, 1.24; 95% CI, 1.15–1.33; P &lt; .001) were patient factors associated with retesting. There was an interaction between method of initial diagnosis of H pylori infection and provider who ordered the initial test (P &lt; .001). There was significant variation in rates of retesting among VHA facilities (P &lt; .001). In an analysis of data from a VHA cohort of patients with H pylori infection, we found low rates of retesting after eradication treatment. There is significant variation in rates of retesting among VHA facilities. H pylori testing is ordered by nongastroenterology specialists two-thirds of the time. Confirming eradication of H pylori is mandatory and widespread quality assurance protocols are needed.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotic</subject><subject>Breath Tests</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Helicobacter Infections - diagnosis</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Resistance</subject><subject>Response to Therapy</subject><subject>Retrospective Studies</subject><subject>Risk Factor</subject><subject>Treatment Outcome</subject><subject>Veterans Health</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9vEzEQxVcIREvhA3BBPnLJ4r_rtZCQoqrQSpGQqsLV8nrHiaNdO9hOUQ98d5wmVHDhNCPPez-P5jXNW4Jbgkn3Ydva9aalmOIWsxYL9aw5J4LThZSEPz_1THTirHmV8xZjqriSL5szRqmklIvz5tcq_kS3pkBG0aFbqE3xYY1cTOgqmdFbU3wMh-E1TN7GwdgCCe0eppg8ugkO7KNg6Q7PdwlMmSEU5AMqG0DfKzGZkKvbTGWDluPsg88lPWJfNy-cmTK8OdWL5tvnq7vL68Xq65eby-VqYbkgZWE7ykEx01NDORtq5U5KKoXtiBuZtKNUVHVU9cyQXlHMxMA4AB8YHRx37KL5dOTu9sMMo60LJjPpXfKzSQ86Gq__nQS_0et4r6XgRChcAe9PgBR_7OuN9OyzhWkyAeI-a8r6vidCMlal5Ci1KeacwD19Q7A-xKa3usamD7FpzHSNrXre_b3fk-NPTlXw8SiAeqV7D0ln6yFYGH2qAegx-v_gfwO6Dqp2</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Kumar, Shria</creator><creator>Metz, David C.</creator><creator>Kaplan, David E.</creator><creator>Goldberg, David S.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3839-336X</orcidid><orcidid>https://orcid.org/0000-0001-9745-2676</orcidid></search><sort><creationdate>20210201</creationdate><title>Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration</title><author>Kumar, Shria ; Metz, David C. ; Kaplan, David E. ; Goldberg, David S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-c624e93a82a243ba824f77275c61fd37cd792962983a1892035b34ee4b32bf4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotic</topic><topic>Breath Tests</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Helicobacter Infections - diagnosis</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Resistance</topic><topic>Response to Therapy</topic><topic>Retrospective Studies</topic><topic>Risk Factor</topic><topic>Treatment Outcome</topic><topic>Veterans Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, Shria</creatorcontrib><creatorcontrib>Metz, David C.</creatorcontrib><creatorcontrib>Kaplan, David E.</creatorcontrib><creatorcontrib>Goldberg, David S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, Shria</au><au>Metz, David C.</au><au>Kaplan, David E.</au><au>Goldberg, David S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>19</volume><issue>2</issue><spage>305</spage><epage>313.e1</epage><pages>305-313.e1</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Expert consensus mandates retesting for eradication of Helicobacter pylori infection after treatment, but it is not clear how many patients are actually retested. We evaluated factors associated with retesting for H pylori in a large, nationwide cohort. We performed a retrospective cohort study of patients with H pylori infection (detected by urea breath test, stool antigen, or pathology) who were prescribed an eradication regimen from January 1, 1994 through December 31, 2018 within the Veterans Health Administration (VHA). We collected data on demographic features, smoking history, socioeconomic status, facility poverty level and academic status, and provider specialties and professions. The primary outcome was retesting for eradication. Statistical analyses included mixed-effects logistic regression. Of 27,185 patients prescribed an H pylori eradication regimen, 6486 patients (23.9%) were retested. Among 7623 patients for whom we could identify the provider who ordered the test, 2663 patients (34.9%) received the order from a gastroenterological provider. Female sex (odds ratio, 1.22; 95% CI, 1.08–1.38; P = .002) and history of smoking (odds ratio, 1.24; 95% CI, 1.15–1.33; P &lt; .001) were patient factors associated with retesting. There was an interaction between method of initial diagnosis of H pylori infection and provider who ordered the initial test (P &lt; .001). There was significant variation in rates of retesting among VHA facilities (P &lt; .001). In an analysis of data from a VHA cohort of patients with H pylori infection, we found low rates of retesting after eradication treatment. There is significant variation in rates of retesting among VHA facilities. H pylori testing is ordered by nongastroenterology specialists two-thirds of the time. Confirming eradication of H pylori is mandatory and widespread quality assurance protocols are needed.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32272245</pmid><doi>10.1016/j.cgh.2020.03.059</doi><orcidid>https://orcid.org/0000-0002-3839-336X</orcidid><orcidid>https://orcid.org/0000-0001-9745-2676</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1542-3565
ispartof Clinical gastroenterology and hepatology, 2021-02, Vol.19 (2), p.305-313.e1
issn 1542-3565
1542-7714
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7541590
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Anti-Bacterial Agents - therapeutic use
Antibiotic
Breath Tests
Drug Therapy, Combination
Female
Helicobacter Infections - diagnosis
Helicobacter Infections - drug therapy
Helicobacter pylori
Humans
Proton Pump Inhibitors - therapeutic use
Resistance
Response to Therapy
Retrospective Studies
Risk Factor
Treatment Outcome
Veterans Health
title Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A28%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20Rates%20of%20Retesting%20for%20Eradication%20of%20Helicobacter%20pylori%20Infection%20After%20Treatment%20in%20the%20Veterans%20Health%20Administration&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Kumar,%20Shria&rft.date=2021-02-01&rft.volume=19&rft.issue=2&rft.spage=305&rft.epage=313.e1&rft.pages=305-313.e1&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2020.03.059&rft_dat=%3Cproquest_pubme%3E2388815733%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2388815733&rft_id=info:pmid/32272245&rft_els_id=S1542356520304365&rfr_iscdi=true